Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Alvotech - Ordinary Shares (NQ:ALVO)

10.32 +0.07 (+0.68%)
Streaming Delayed Price Updated: 11:50 AM EDT, May 13, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 76,275
Open 10.30
Bid (Size) 10.34 (6)
Ask (Size) 10.35 (2)
Prev. Close 10.25
Today's Range 10.06 - 10.35
52wk Range 7.350 - 14.65
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Alvotech Meets Investors and Participates in Fireside Chat At the BofA Securities Healthcare Conference 2025 in Las Vegas, Nevada
From Alvotech
Via GlobeNewswire
Groupon Posts Upbeat Earnings, Joins Axon Enterprise, Warner Bros. Discovery, MercadoLibre And Other Big Stocks Moving Higher On Thursday
Via Benzinga

Performance

YTD
-21.6%
-21.6%
1 Month
+21.0%
+21.0%
3 Month
-19.1%
-19.1%
6 Month
-15.5%
-15.5%
1 Year
-22.3%
-22.3%

More News

Read More
12 Health Care Stocks Moving In Wednesday's After-Market Session
Via Benzinga
Earnings Scheduled For May 7, 2025
Via Benzinga
Alvotech's Earnings Outlook
Via Benzinga
Alvotech Reports Results for the First Quarter of 2025 and Provides Business Update
From Alvotech
Via GlobeNewswire
Potential U.S. Tariffs on Pharmaceuticals Expected to Have Minimal Impact on Alvotech’s Product Revenues in 2025
From Alvotech
Via GlobeNewswire
Why Is Israel-Based Generic Drug Focused Teva Pharmaceutical Stock Trading Higher On Monday?
Via Benzinga
Exposures Product Safety
Teva and Alvotech Announce FDA Approval of Interchangeability for SELARSDI™ (ustekinumab-aekn) with Stelara® (ustekinumab)
From Teva Pharmaceutical Industries Ltd
Via GlobeNewswire
Alvotech Announces Webcast of First Quarter 2025 Financial Results on May 8, 2025, at 8:00 am EDT
From Alvotech
Via GlobeNewswire
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
Alvotech Appoints Dr. Balaji V. Prasad as Chief Strategy Officer
From Alvotech
Via GlobeNewswire
Alvotech Reports Record Results for 2024 and Provides Business Update
From Alvotech
Via GlobeNewswire
12 Health Care Stocks Moving In Wednesday's After-Market Session
Via Benzinga
Earnings Scheduled For March 26, 2025
Via Benzinga
UK Medicines and Healthcare Products Regulatory Agency Confirms Acceptance of Marketing Authorization Application for Proposed Biosimilar to Xolair® (omalizumab)
From Alvotech
Via GlobeNewswire
Alvotech Strengthens Biosimilar Portfolio With $27 Million Xbrane R&D Deal
Via Benzinga
Alvotech Acquires Xbrane’s R&D Operations in Sweden and Further Affirms its Global Leadership Position in Biosimilars Development and Production
From Alvotech
Via GlobeNewswire
Alvotech and Dr. Reddy’s Announce FDA Acceptance of Biologic License Application for AVT03, a Proposed Biosimilar to Prolia® and Xgeva®
From Dr. Reddy’s Laboratories Ltd.
Via Business Wire
Alvotech and Dr. Reddy’s Announce FDA acceptance of Biologic License Application for AVT03, a Proposed Biosimilar to Prolia® and Xgeva®
From Alvotech
Via GlobeNewswire
Alvotech Meeting Investors and Participates in Fireside Chat At Barclays 27th Global Healthcare Conference in Miami, Florida
From Alvotech
Via GlobeNewswire
Teva and Alvotech Announce SELARSDI™ (ustekinumab-aekn) Injection Now Available in the U.S.
From Teva Pharmaceutical Industries Ltd
Via GlobeNewswire
Alvotech and Teva Announce Filing Acceptance of U.S. Biologics License Application for AVT06, a Proposed Biosimilar to Eylea® (aflibercept)
From Teva Pharmaceutical Industries Ltd; Alvotech
Via GlobeNewswire
Why IMAC Holdings Shares Are Trading Higher By Over 108%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Alvotech and Teva Announce Filing Acceptance of U.S. Biologics License Applications for AVT05, a Proposed Biosimilar to Simponi® and Simponi Aria® (golimumab)
From Alvotech
Via GlobeNewswire

Frequently Asked Questions

Is Alvotech - Ordinary Shares publicly traded?
Yes, Alvotech - Ordinary Shares is publicly traded.
What exchange does Alvotech - Ordinary Shares trade on?
Alvotech - Ordinary Shares trades on the Nasdaq Stock Market
What is the ticker symbol for Alvotech - Ordinary Shares?
The ticker symbol for Alvotech - Ordinary Shares is ALVO on the Nasdaq Stock Market
What is the current price of Alvotech - Ordinary Shares?
The current price of Alvotech - Ordinary Shares is 10.32
When was Alvotech - Ordinary Shares last traded?
The last trade of Alvotech - Ordinary Shares was at 05/13/25 11:50 AM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.